Optical coherence tomography angiography findings in retinal vein occlusion treated with anti-vascular endothelial growth factor

Session Details

Session Title: Free Paper Session 11: Vascular Diseases & Diabetic Retinopathy III

Session Date/Time: Friday 08/09/2017 | 11:00-12:30

Paper Time: 12:12

Venue: Room 114

First Author: : S.Yu SOUTH KOREA

Co Author(s): :    D. Kim   E. Kim                          

Abstract Details


To analyze patients with retinal vein occlusion using optical coherence tomography angiography (OCT-A) before and after anti-vascular endothelial growth factor (VEGF) therapy.


Department of Ophthalmology, Kyung Hee University Hospital, Seoul, Korea


Retrospective review of retinal vein occlusion with secondary macular edema patients treated with anti-VEGF and a minimum follow-up of 3 months between May 2016 and January 2017. Best-corrected visual acuity (BCVA), central retinal thickness (CRT) were assessed before and after treatment. The vascular change and nonperfused areas were evaluated with OCT-A.


The study analyzed 40 eyes of 40 patients (mean ages, 65.4 years), including 11 cases of central RVO, 23 cases of branch RVO and 6 cases of hemi-central RVO. All patients received anti-VEGF treatment of RVO with secondary macular edema at least once more intravitreal injection. The mean follow-up period was 5.5 months. After treatment, the logMAR BCVA significantly improved from 0.51±0.13 to 0.28±0.17 (p<0.01) and mean central retinal thickness significantly decreased from 405.13±142.0µm to 294.50±102.73µm (p<0.01). The perifoveal capillary disruption, the number of intraretinal cyst and venous dilatation in retinal superficial and deep capillary layers was significantly decreased after treatment using OCT-A. The nonperfused areas of after treatment was significantly decreased rather than baseline.


The study showed reduction of non-perfused areas and improvement of retinal vascular flow after anti-VEGF treatment on OCT-A. OCT-A was effective and non-invasive diagnostic tool for RVO with secondary macular edema especially observing changes in the area of the nonperfused areas due to ischaemia.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy